These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 10178664)

  • 21. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.
    Karnon J
    Health Econ; 2003 Oct; 12(10):837-48. PubMed ID: 14508868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility.
    Marsh K; Xu P; Orfanos P; Gordon J; Griebsch I
    Pharmacoeconomics; 2014 Oct; 32(10):981-93. PubMed ID: 25016596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.
    Hughes D; Cowell W; Koncz T; Cramer J;
    Value Health; 2007; 10(6):498-509. PubMed ID: 17970932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incorporation of uncertainty in health economic modelling studies.
    Nuijten M
    Pharmacoeconomics; 2005; 23(8):851-3; author reply 853. PubMed ID: 16097845
    [No Abstract]   [Full Text] [Related]  

  • 25. A taxonomy of model structures for economic evaluation of health technologies.
    Brennan A; Chick SE; Davies R
    Health Econ; 2006 Dec; 15(12):1295-310. PubMed ID: 16941543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A New Method for Model-Based Health Economic Evaluation Utilizing and Extending Moment-Generating Functions.
    Snowsill T
    Med Decis Making; 2019 Jul; 39(5):523-539. PubMed ID: 31319752
    [No Abstract]   [Full Text] [Related]  

  • 27. A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources.
    Haji Ali Afzali H; Karnon J; Gray J
    Pharmacoeconomics; 2012 Jun; 30(6):461-82. PubMed ID: 22462694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.
    Stahl JE
    Pharmacoeconomics; 2008; 26(2):131-48. PubMed ID: 18198933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Scalable approximate policies for Markov decision process models of hospital elective admissions.
    Zhu G; Lizotte D; Hoey J
    Artif Intell Med; 2014 May; 61(1):21-34. PubMed ID: 24791675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling in pharmacoeconomic studies: funding sources and outcomes.
    Garattini L; Koleva D; Casadei G
    Int J Technol Assess Health Care; 2010 Jul; 26(3):330-3. PubMed ID: 20584363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Application of Markov model in post-marketing pharmacoeconomic evaluation of traditional Chinese medicine].
    Wang X; Su X; Sun W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2844-7. PubMed ID: 22292381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of models within economic analysis: focus on type 2 diabetes mellitus.
    Coyle D; Lee KM; O'Brien BJ
    Pharmacoeconomics; 2002; 20 Suppl 1():11-9. PubMed ID: 12036380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fuzzy Stochastic Optimal Guaranteed Cost Control of Bio-Economic Singular Markovian Jump Systems.
    Li L; Zhang Q; Zhu B
    IEEE Trans Cybern; 2015 Nov; 45(11):2512-21. PubMed ID: 25608319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Translating Pharmacometrics to a Pharmacoeconomic Model of COPD.
    Slejko JF; Willke RJ; Ribbing J; Milligan P
    Value Health; 2016 Dec; 19(8):1026-1032. PubMed ID: 27987629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Disease modelling in diabetes mellitus].
    Schramm W; Schöffski O; Görtz A; Liebl A
    Dtsch Med Wochenschr; 2004 Oct; 129(43):2305-10. PubMed ID: 15483770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis.
    Landfeldt E; Alfredsson L; Straub V; Lochmüller H; Bushby K; Lindgren P
    Pharmacoeconomics; 2017 Feb; 35(2):249-258. PubMed ID: 27798808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoeconomic analyses using discrete event simulation.
    Caro JJ
    Pharmacoeconomics; 2005; 23(4):323-32. PubMed ID: 15853433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.
    Wlodarczyk JH; Cleland LG; Keogh AM; McNeil KD; Perl K; Weintraub RG; Williams TJ
    Pharmacoeconomics; 2006; 24(9):903-15. PubMed ID: 16942124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic consequences of the progression of rheumatoid arthritis in Sweden.
    Kobelt G; Eberhardt K; Jönsson L; Jönsson B
    Arthritis Rheum; 1999 Feb; 42(2):347-56. PubMed ID: 10025930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling treatment of ischemic heart disease with partially observable Markov decision processes.
    Hauskrecht M; Fraser H
    Proc AMIA Symp; 1998; ():538-42. PubMed ID: 9929277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.